文献速递生殖医学妇科

辅助生殖前使用促性腺激素释放激素激动剂抑制垂体可能不足以治疗重度子宫腺肌症女性

Pituitary suppression with GnRH agonists before ART may be insufficient to treat women with severe adenomyosis.
PubMed 文献 · Reprod Biomed Online · 2022-10-01

研究探讨芳香化酶抑制剂能否通过减少局部雌激素生成改善接受长期促性腺激素释放激素激动剂(GnRHa)治疗的重度子宫腺肌症患者的体外受精结局。四例重度子宫腺肌症患者在长期(≥3个月)GnRHa治疗未改善后接受芳香化酶抑制剂治疗21天,监测雌二醇浓度并接受自体或供卵体外受精胚胎移植。结果显示芳香化酶抑制剂降低高雌激素状态并改善既往胚胎移植失败患者的临床结局,作者认为来曲唑安全且可改善体外受精结局。

要点

  • 重度子宫腺肌症患者即使长期GnRHa治疗后,病灶局部仍产生雌激素导致高雌激素状态。
  • 芳香化酶抑制剂治疗21天可降低高雌激素状态并改善既往胚胎移植失败患者的临床结局。
  • 作者认为对接受长期GnRHa治疗的重度子宫腺肌症患者应检测雌二醇浓度。

核心结论

  • 重度子宫腺肌症女性在辅助生殖技术治疗前可能从来曲唑或GnRHa联合来曲唑中获益。
  • 对重度子宫腺肌症女性,单用GnRHa可能不足以抑制腺肌症病灶产生雌激素。
  • 作者认为对接受长期GnRHa治疗的重度子宫腺肌症患者应检测雌二醇浓度。
  • 作者认为GnRHa可能不总是腺肌症病灶药物治疗的唯一策略,来曲唑安全且可改善子宫腺肌症患者的体外受精结局。

研究设计与样本

  • 四例重度子宫腺肌症患者在长期(≥3个月)长效GnRHa治疗未改善后,接受芳香化酶抑制剂治疗21天。
  • 监测GnRHa治疗后及芳香化酶抑制剂治疗后的血雌二醇浓度。
  • 患者接受自体或供卵体外受精胚胎移植,主要结局为妊娠率和持续妊娠率,次要结局为芳香化酶抑制剂治疗后的血雌二醇浓度。

主要发现

  • 重度子宫腺肌症患者在长期GnRHa治疗后仍因病灶局部产生雌激素而表现为高雌激素状态。
  • 芳香化酶抑制剂治疗降低高雌激素状态并改善既往胚胎移植失败患者的临床结局。

临床怎么用

  • 作者认为重度子宫腺肌症女性在辅助生殖技术治疗前可能从来曲唑或GnRHa联合来曲唑中获益。
  • 作者认为对接受长期GnRHa治疗的重度子宫腺肌症患者应检测雌二醇浓度。
  • 作者认为来曲唑安全且可改善子宫腺肌症患者的体外受精结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RESEARCH QUESTION: Does aromatase inhibitor improve IVF outcomes by reducing local oestrogen production in patients with adenomyosis undergoing long-term gonadotrophin-releasing hormone agonist (GnRHa) treatment? DESIGN: Four patients with severe adenomyosis who failed to improve after long-term treatment (≥3 months) with depot GnRHa received treatment with an aromatase inhibitor for 21 days. Blood oestradiol concentrations were monitored after GnRHa treatment both before and after treatment with an aromatase inhibitor. Women received a transfer of IVF autologous or donor oocytes. Pregnancy and ongoing pregnancy rates were the primary outcomes. Blood oestradiol concentration after treatment with an aromatase inhibitor was a secondary outcome. RESULTS: Patients with severe adenomyosis presented with hyperestrogenism due to local production from the lesions even after long-term treatment with GnRHa. Treatment with an aromatase inhibitor reduced hyperestrogenism and improved clinical outcomes in adenomyosis patients who have experienced previous embryo transfer failures. CONCLUSION: Women with severe adenomyosis would benefit from letrozole or a combination of GnRHa plus letrozole before receipt of treatment with assisted reproductive technology. For women with severe adenomyosis, GnRHa treatment alone may be insufficient to suppress oestrogen production by adenomyotic lesions. Thus, it should be mandatory to test for oestradiol concentrations in patients with severe adenomyosis who have received long-term GnRHa treatment. Also, GnRHa may not always be the sole strategy for medical management of adenomyotic lesions. Letrozole is safe and can improve IVF outcomes for patients with adenomyosis.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Cozzolino M, Pellicer N, Galliano D, et al. Pituitary suppression with GnRH agonists before ART may be insufficient to treat women with severe adenomyosis. Reprod Biomed Online. 2022. PMID: 36402667. doi:10.1016/j.rbmo.2022.09.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。